文献速递关节外科

AAHKS临床研究奖:全膝关节置换术后口服地塞米松:一项双盲随机对照试验

The AAHKS Clinical Research Award: Oral Dexamethasone Following Total Knee Arthroplasty: A Double-Blind, Randomized Controlled Trial.
PubMed 文献 · J Arthroplasty · 2023-04-25

这项双盲随机安慰剂对照试验将109例连续初次全膝关节置换患者随机分组,A组57例术后第1天起口服地塞米松4 mg每日两次共4天,B组服安慰剂。地塞米松组术后第1至4天平均VAS评分显著降低(P=0.01),第2、3、4天及晨间和午间VAS评分显著更低;阿片类药物使用、恶心呕吐、90天并发症、行走辅助、睡眠困难和早期患者报告结局两组无差异。作者认为口服地塞米松可减轻术后疼痛,在静脉给药受限的门诊手术中可能是有益选择,但需更大样本进一步评估安全性。

要点

  • 初次全膝关节置换术后口服地塞米松4 mg每日两次共4天,术后第1至4天平均VAS评分显著降低(P=0.01)。
  • 地塞米松组术后第2、3、4天以及晨间和午间VAS评分显著更低。
  • 阿片类药物使用、恶心呕吐、90天并发症、行走辅助、睡眠困难和早期患者报告结局两组无差异。

核心结论

  • 这项双盲随机安慰剂对照试验表明,初次全膝关节置换术后口服地塞米松可减轻术后疼痛。
  • 作者认为在静脉给药受限的门诊手术中口服地塞米松可能是有益选择,但需更大样本进一步评估该人群的安全性。

研究设计与样本

  • 双盲、随机、安慰剂对照试验,前瞻性随机纳入109例连续接受初次全膝关节置换的患者。
  • A组57例术后第1天起口服地塞米松4 mg每日两次共4天,B组服用安慰剂胶囊,所有医护人员和患者对分组设盲。
  • 主要结局为术后疼痛评分,次要结局包括90天术后并发症、恶心呕吐、每日阿片类药物用量、行走辅助、睡眠困难和早期患者报告结局。

主要发现

  • 地塞米松组术后第1至4天平均VAS评分较安慰剂组显著降低(P=0.01)。
  • 地塞米松组术后第2、3、4天各单日平均VAS评分显著低于安慰剂组。
  • 服用地塞米松期间,晨间和午间VAS评分显著低于安慰剂组。
  • 两组在阿片类药物使用、恶心呕吐、90天并发症、能否在辅助下行走、睡眠困难和早期患者报告结局方面无差异。
  • 两组人口学特征相似。

关键数值与推荐

  • A组57例患者术后第1天起口服地塞米松4 mg每日两次共4天。
  • 主要结局术后第1至4天平均VAS评分地塞米松组较安慰剂组显著降低(P=0.01)。

临床怎么用

  • 作者认为口服地塞米松在静脉给药受限的门诊手术中可能是有益选择,但需更大样本进一步评估该人群的安全性。

局限性

  • 作者指出需更大样本进一步评估口服地塞米松在该人群中的安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intravenous dexamethasone has been shown to reduce pain in total joint arthroplasty. This double-blind, randomized, placebo-controlled trial investigated the postoperative effects and safety of oral dexamethasone as a potential augment to multimodal pain management in outpatient knee arthroplasty. METHODS: The authors prospectively randomized 109 consecutive patients undergoing primary total knee arthroplasty. Patients assigned to Group A (57 patients) received 4 mg of dexamethasone by mouth twice per day starting postoperative day (POD) 1 for 4 days and those assigned to Group B received placebo capsules. All healthcare professionals and patients were blinded to group allocation. The primary outcome was defined as postoperative pain scores. Secondary outcomes included 90-day postoperative complications, nausea and vomiting, daily opioid usage, assistance for ambulation, difficulty sleeping, and early patient reported outcomes. Demographics were similar between groups. RESULTS: The patients who received dexamethasone had a statistically significant decrease in VAS scores when averaging POD 1 to 4 (P = .01). The average VAS scores among individual days were significantly lower with dexamethasone on POD 2, 3, and 4. While taking dexamethasone, morning and mid-day VAS scores were significantly lower. There was no difference between the groups with opioid use, nausea or vomiting, 90-day complications, ability to walk with/without assistance, difficulty sleeping, and early patient reported outcomes. CONCLUSION: This double-blind, randomized, placebo-controlled trial demonstrated that oral dexamethasone following primary total knee arthroplasty can reduce postoperative pain. This may be a beneficial option in ambulatory surgery where intravenous limitations exist, but larger series are needed to further evaluate the safety profile in this population.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Shaw JH, Wesemann LD, Banka TR, et al. The AAHKS Clinical Research Award: Oral Dexamethasone Following Total Knee Arthroplasty: A Double-Blind, Randomized Controlled Trial. J Arthroplasty. 2023. PMID: 37105325. doi:10.1016/j.arth.2023.04.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。